Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

5.98
Delayed Data
As of Jan 28
 +0.37 / +6.60%
Today’s Change
2.53
Today|||52-Week Range
8.10
+9.93%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$170.3M

Company Description

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Contact Information

Corvus Pharmaceuticals, Inc.
863 Mitten Road
Burlingame California 94010
P:(650) 900-4520
Investor Relations:
(650) 900-4522

Employees

Shareholders

Mutual fund holders8.07%
Individual stakeholders66.15%
Other institutional49.91%

Top Executives

There are no executives to display.